On Nov 14, major Wall Street analysts update their ratings for $Corvus Pharmaceuticals (CRVS.US)$, with price targets ranging from $13 to $24.
Jefferies analyst Roger Song initiates coverage with a buy rating, and sets the target price at $13.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
Oppenheimer analyst Jeff Jones maintains with a buy rating, and adjusts the target price from $8 to $14.
Ladenburg Thalmann analyst Aydin Huseynov maintains with a buy rating, and adjusts the target price from $21 to $24.
Furthermore, according to the comprehensive report, the opinions of $Corvus Pharmaceuticals (CRVS.US)$'s main analysts recently are as follows:
Anticipation is building for the upcoming report of Phase 1 interim data from soquelitinib in atopic dermatitis scheduled for December. The early data from the initial doses may furnish clinical proof of concept for the oral ITK inhibitor's potential in a wider range of inflammation and immunology applications.
Following the company's quarterly results, there is a positive outlook for the upcoming atopic dermatitis readout expected in December, illustrated by management's enthusiasm. Despite a constrained cash situation due to the level of clinical activity, the company reported having sufficient funds to continue operations into early 2026.
Here are the latest investment ratings and price targets for $Corvus Pharmaceuticals (CRVS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月14日，多家华尔街大行更新了$Corvus Pharmaceuticals (CRVS.US)$的评级，目标价介于13美元至24美元。
富瑞集团分析师Roger Song首予买入评级，目标价13美元。
瑞穗证券分析师Graig Suvannavejh维持买入评级。
奥本海默控股分析师Jeff Jones维持买入评级，并将目标价从8美元上调至14美元。
Ladenburg Thalmann分析师Aydin Huseynov维持买入评级，并将目标价从21美元上调至24美元。
此外，综合报道，$Corvus Pharmaceuticals (CRVS.US)$近期主要分析师观点如下：
以下为今日4位分析师对$Corvus Pharmaceuticals (CRVS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
